Format

Send to

Choose Destination
Biol Chem. 2018 Oct 6. pii: /j/bchm.ahead-of-print/hsz-2018-0335/hsz-2018-0335.xml. doi: 10.1515/hsz-2018-0335. [Epub ahead of print]

Microbial transglutaminase for biotechnological and biomedical engineering.

Author information

1
Institute for Organic Chemistry and Biochemistry, Technische Universität Darmstadt, Alarich-Weiss-Straße 4, D-64287 Darmstadt, Germany.

Abstract

Research on bacterial transglutaminase dates back to 1989, when the enzyme has been isolated from Streptomyces mobaraensis. Initially discovered during an extensive screening campaign to reduce costs in food manufacturing, it quickly appeared as a robust and versatile tool for biotechnological and pharmaceutical applications due to its excellent activity and simple handling. While pioneering attempts to make use of its extraordinary cross-linking ability resulted in heterogeneous polymers, currently it is applied to site-specifically ligate diverse biomolecules yielding precisely modified hybrid constructs comprising two or more components. This review covers the extensive and rapidly growing field of microbial transglutaminase-mediated bioconjugation with the focus on pharmaceutical research. In addition, engineering of the enzyme by directed evolution and rational design is highlighted. Moreover, cumbersome drawbacks of this technique mainly caused by the enzyme's substrate indiscrimination are discussed as well as the ways to bypass these limitations.

KEYWORDS:

antibody-drug conjugates; bioconjugation; microbial transglutaminase; protein PEGylation; protein labeling

PMID:
30291779
DOI:
10.1515/hsz-2018-0335

Supplemental Content

Full text links

Icon for Sheridan PubFactory
Loading ...
Support Center